Medical experts have begun using ketamine, an old anesthesia drug with psychedelic qualities, to help with treatment-resistant depression, post-traumatic stress disorder and anxiety. Now, doctors are ...

A Placer County man is sharing his personal story of recovery from severe suicidal depression. David Bartley found relief in ...

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.

Learn about five serious mental health conditions that often necessitate inpatient treatment. Understanding these challenges ...

Avesta Ketamine and Wellness (Avesta), the leading provider of monitored ketamine care in the Washington, D.C., Maryland and ...

Canaccord analyst Sumant Kulkarni lowered the firm’s price target on Compass Pathways (CMPS) to $15 from $23 and keeps a Buy rating on the ...

In South Florida, innovative ideas are being employed every day to deal with climate change threats. Start-up tech companies ...

NEW YORK, NY / ACCESS Newswire / February 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...

A local psychiatrist is taking a unique approach to treating depression at his Saratoga County practice. Manuel Astruc, M.D. & Associates provides Transcranial Magnetic Stimulation Therapy. It's a non ...

Despite a significant net loss, Compass Pathways PLC (CMPS) secures financing to advance key clinical trials and strengthen its financial position.

Stifel has initiated Compass Pathways (NASDAQ:CMPS) with a buy rating saying that stakeholders are starting to agree there is ...

Discover how cannabinoid receptor type 1 (CB1) influences resilience to stress and its potential in treating anxiety and ...